121 related articles for article (PubMed ID: 9434204)
1. Neurobehavioral effects of anandamide and cannabinoid receptor gene expression in mice.
Chakrabarti A; Ekuta JE; Onaivi ES
Brain Res Bull; 1998; 45(1):67-74. PubMed ID: 9434204
[TBL] [Abstract][Full Text] [Related]
2. Assessment of anandamide interaction with the cannabinoid brain receptor: SR 141716A antagonism studies in mice and autoradiographic analysis of receptor binding in rat brain.
Adams IB; Compton DR; Martin BR
J Pharmacol Exp Ther; 1998 Mar; 284(3):1209-17. PubMed ID: 9495885
[TBL] [Abstract][Full Text] [Related]
3. Cannabinoid-induced mesenteric vasodilation through an endothelial site distinct from CB1 or CB2 receptors.
Járai Z; Wagner JA; Varga K; Lake KD; Compton DR; Martin BR; Zimmer AM; Bonner TI; Buckley NE; Mezey E; Razdan RK; Zimmer A; Kunos G
Proc Natl Acad Sci U S A; 1999 Nov; 96(24):14136-41. PubMed ID: 10570211
[TBL] [Abstract][Full Text] [Related]
4. Cannabinoid ligand-receptor signaling in the mouse uterus.
Das SK; Paria BC; Chakraborty I; Dey SK
Proc Natl Acad Sci U S A; 1995 May; 92(10):4332-6. PubMed ID: 7753807
[TBL] [Abstract][Full Text] [Related]
5. The endogenous cannabinoid anandamide is a lipid messenger activating cell growth via a cannabinoid receptor-independent pathway in hematopoietic cell lines.
Derocq JM; Bouaboula M; Marchand J; Rinaldi-Carmona M; Ségui M; Casellas P
FEBS Lett; 1998 Apr; 425(3):419-25. PubMed ID: 9563506
[TBL] [Abstract][Full Text] [Related]
6. Delta9-tetrahydrocannabinol, but not the endogenous cannabinoid receptor ligand anandamide, produces conditioned place avoidance.
Mallet PE; Beninger RJ
Life Sci; 1998; 62(26):2431-9. PubMed ID: 9651110
[TBL] [Abstract][Full Text] [Related]
7. Dose-response effects of systemic anandamide administration in mice sequentially submitted to the open field and elevated plus-maze tests.
Ribeiro A; Ferraz-de-Paula V; Pinheiro ML; Palermo-Neto J
Braz J Med Biol Res; 2009 Jun; 42(6):556-60. PubMed ID: 19448906
[TBL] [Abstract][Full Text] [Related]
8. Neurobehavioral effects of delta 9-THC and cannabinoid (CB1) receptor gene expression in mice.
Onaivi ES; Chakrabarti A; Gwebu ET; Chaudhuri G
Behav Brain Res; 1995 Dec; 72(1-2):115-25. PubMed ID: 8788864
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of intestinal motility by anandamide, an endogenous cannabinoid.
Calignano A; La Rana G; Makriyannis A; Lin SY; Beltramo M; Piomelli D
Eur J Pharmacol; 1997 Dec; 340(2-3):R7-8. PubMed ID: 9537804
[TBL] [Abstract][Full Text] [Related]
10. Anandamide-induced neuroblastoma cell rounding via the CB1 cannabinoid receptors.
Ishii I; Chun J
Neuroreport; 2002 Apr; 13(5):593-6. PubMed ID: 11973452
[TBL] [Abstract][Full Text] [Related]
11. Cannabinomimetic behavioral effects of and adenylate cyclase inhibition by two new endogenous anandamides.
Barg J; Fride E; Hanus L; Levy R; Matus-Leibovitch N; Heldman E; Bayewitch M; Mechoulam R; Vogel Z
Eur J Pharmacol; 1995 Dec; 287(2):145-52. PubMed ID: 8749028
[TBL] [Abstract][Full Text] [Related]
12. Levels, metabolism, and pharmacological activity of anandamide in CB(1) cannabinoid receptor knockout mice: evidence for non-CB(1), non-CB(2) receptor-mediated actions of anandamide in mouse brain.
Di Marzo V; Breivogel CS; Tao Q; Bridgen DT; Razdan RK; Zimmer AM; Zimmer A; Martin BR
J Neurochem; 2000 Dec; 75(6):2434-44. PubMed ID: 11080195
[TBL] [Abstract][Full Text] [Related]
13. Role of CB1 and CB2 receptors in the inhibitory effects of cannabinoids on lipopolysaccharide-induced nitric oxide release in astrocyte cultures.
Molina-Holgado F; Molina-Holgado E; Guaza C; Rothwell NJ
J Neurosci Res; 2002 Mar; 67(6):829-36. PubMed ID: 11891798
[TBL] [Abstract][Full Text] [Related]
14. The pharmacological activity of anandamide, a putative endogenous cannabinoid, in mice.
Smith PB; Compton DR; Welch SP; Razdan RK; Mechoulam R; Martin BR
J Pharmacol Exp Ther; 1994 Jul; 270(1):219-27. PubMed ID: 8035318
[TBL] [Abstract][Full Text] [Related]
15. The endogenous cannabinoid receptor ligand, anandamide, inhibits the motor behavior: role of nigrostriatal dopaminergic neurons.
Romero J; García L; Cebeira M; Zadrozny D; Fernández-Ruiz JJ; Ramos JA
Life Sci; 1995; 56(23-24):2033-40. PubMed ID: 7776829
[TBL] [Abstract][Full Text] [Related]
16. CB1 cannabinoid receptor-mediated anandamide signaling mechanisms of the inferior colliculus modulate the haloperidol-induced catalepsy.
Medeiros P; de Freitas RL; Silva MO; Coimbra NC; Melo-Thomas L
Neuroscience; 2016 Nov; 337():17-26. PubMed ID: 27595886
[TBL] [Abstract][Full Text] [Related]
17. Biphasic effects of anandamide.
Sulcova E; Mechoulam R; Fride E
Pharmacol Biochem Behav; 1998 Feb; 59(2):347-52. PubMed ID: 9476980
[TBL] [Abstract][Full Text] [Related]
18. Pharmacological activity of the cannabinoid receptor agonist, anandamide, a brain constituent.
Fride E; Mechoulam R
Eur J Pharmacol; 1993 Feb; 231(2):313-4. PubMed ID: 8384116
[TBL] [Abstract][Full Text] [Related]
19. Characterization of a novel endocannabinoid, virodhamine, with antagonist activity at the CB1 receptor.
Porter AC; Sauer JM; Knierman MD; Becker GW; Berna MJ; Bao J; Nomikos GG; Carter P; Bymaster FP; Leese AB; Felder CC
J Pharmacol Exp Ther; 2002 Jun; 301(3):1020-4. PubMed ID: 12023533
[TBL] [Abstract][Full Text] [Related]
20. Suppression of nerve growth factor Trk receptors and prolactin receptors by endocannabinoids leads to inhibition of human breast and prostate cancer cell proliferation.
Melck D; De Petrocellis L; Orlando P; Bisogno T; Laezza C; Bifulco M; Di Marzo V
Endocrinology; 2000 Jan; 141(1):118-26. PubMed ID: 10614630
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
